Astrazeneca Pharma India Ltd
₹5957
+6.50 (0.11%)
Thu, 22 Oct 2026, 08:37 pm
Health Technology
Pharmaceuticals: Major
24.5KAstrazeneca Pharma India Return on Equity (ROE) History
| Particulars | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 29.61 | 30.61 | 26.62 | 16.73 | 41.18 | 60.81 | 262.27 | 0 | 0 | 0 | 550.79 | 117.59 | 89.09 | 91.75 | 82.80 | 80.66 | 103.71 | 81.76 | 82.35 | 185.90 |
| Price to book ratio | 10.03 | 10.52 | 10.27 | 10.63 | 16.42 | 17.36 | 27.40 | 16.39 | 16.08 | 15.21 | 18.53 | 10.55 | 9.38 | 16.61 | 16.41 | 19.61 | 14.55 | 15.72 | 20.80 | 30.82 |
| Price to sales ratio | 5.66 | 5.53 | 5.38 | 3.49 | 5.98 | 6.57 | 9.51 | 4.19 | 5.83 | 4.89 | 5.13 | 4.33 | 4.06 | 6.86 | 7.19 | 9.31 | 7.93 | 8.09 | 10.27 | 12.54 |
| Price to cash flow ratio | 41.19 | 25.14 | 37.56 | 13.51 | 65.23 | 44.69 | 120.68 | 0 | 972.64 | 0 | 46.80 | 53.74 | 138.20 | 75.69 | 60.18 | 65.96 | 57.09 | 99.68 | 221.83 | 221.49 |
| Enterprise value | 1208Cr | 1383Cr | 1525Cr | 1154Cr | 2306Cr | 3044Cr | 5135Cr | 1616Cr | 2671Cr | 2267Cr | 2815Cr | 2236Cr | 2190Cr | 4822Cr | 5738Cr | 7185Cr | 5949Cr | 7625Cr | 12800Cr | 21015Cr |
| Enterprise value to EBITDA ratio | 19.65 | 19.16 | 16.91 | 10.25 | 25.70 | 36.69 | 114.81 | 0 | 0 | 0 | 168.15 | 59.71 | 44.76 | 67.12 | 47.01 | 54.18 | 67.31 | 45.59 | 68.56 | 81.55 |
| Debt to equity ratio | 0 | 0 | 0 | 0.54 | 0.01 | 0.05 | 0.01 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.03 | 0.03 | 0.02 | 0.01 | 0.01 | 0.05 |
| Return on equity % | 38.66 | 36.25 | 40.83 | 53.61 | 44.21 | 31.65 | 10.71 | -61.95 | -0.38 | -12.93 | 3.43 | 10.58 | 12.12 | 19.88 | 21.71 | 24.94 | 14.97 | 20.79 | 27.95 | 17.31 |
Astrazeneca Pharma India Ltd Return on Equity
The Astrazeneca Pharma India Ltd Return on Equity is a key financial metric used by investors to evaluate Astrazeneca Pharma India Ltd's valuation, profitability, and overall financial performance. Tracking the Astrazeneca Pharma India Ltd Return on Equity helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Astrazeneca Pharma India Ltd (NSE: ASTRAZEN, BSE: 506820) is currently trading at ₹5957, with a market capitalization of ₹14717.5Cr. As a leading company in the Health technology sector and Pharmaceuticals: major industry, monitoring the Astrazeneca Pharma India Ltd Return on Equity is essential for fundamental analysis.
Astrazeneca Pharma India Ltd Return on Equity Current Value
The current Astrazeneca Pharma India Ltd Return on Equity stands at 17.31.
The Astrazeneca Pharma India Ltd Return on Equity has declined compared to earlier levels, suggesting improved fundamentals or more attractive valuation.
Astrazeneca Pharma India Ltd Return on Equity Historical Trend
The Astrazeneca Pharma India Ltd Return on Equity has shown the following historical trend:
- 2025: 17.31
- 2024: 27.95
- 2023: 20.79
- 2022: 14.97
- 2021: 24.94
The decline in Astrazeneca Pharma India Ltd Return on Equity indicates improving financial efficiency or better earnings growth.
What Astrazeneca Pharma India Ltd Return on Equity Indicates for Investors
The Astrazeneca Pharma India Ltd Return on Equity plays a crucial role in understanding the company's financial health and valuation.
ROE indicates how efficiently the company generates returns for shareholders.
Astrazeneca Pharma India Ltd Return on Equity Analysis Summary
The Astrazeneca Pharma India Ltd Return on Equity remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Astrazeneca Pharma India Ltd Return on Equity should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Astrazeneca Pharma India Ltd Return on Equity helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.
